Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)

NCT ID: NCT00636506

Last Updated: 2019-07-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate modifications to the AMS 700 Series pump, cylinders, reservoir and rear tip extender design, their impact on ease of use for the patient, and ease of implantation for the physician.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Erectile dysfunction, the inability to attain or sustain a penile erection sufficient to permit satisfactory sexual intercourse, affects an estimated ten to 30 million men in the United States. Erectile dysfunction can be caused by many organic abnormalities, including diabetes mellitus, hypertension, vascular disease, neurogenic disorders, and other chronic diseases. Erectile dysfunction can be effectively treated with a variety of methods, including the implantation of an inflatable penile prosthesis. A multi-center trial is to be conducted to assess the AMS IPP 2002 Inflatable Penile Prosthesis including handling during IPP implantation procedures and short-term follow-up experience of subjects. The study will collect pre-operative information comparing the pump operation using scrotal models of the current pump with the study pump, and baseline erectile function history. Surgical data will be collected to assess device design and procedure enhancements. Patient and physician assessment of study device function, ease of use, ease of training/learning, and adverse events will be gathered post-operatively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMS 700 IPP 2005 Implant Group

Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.

Group Type EXPERIMENTAL

AMS 700 IPP with MS Pump

Intervention Type DEVICE

AMS 700 Series Inflatable Penile Prosthesis with MS Pump

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMS 700 IPP with MS Pump

AMS 700 Series Inflatable Penile Prosthesis with MS Pump

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMS IPP 2005

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible to participate in this study, male subjects must meet the following requirements:
1. The subject has been diagnosed with erectile dysfunction and has made an informed decision to be implanted with the AMS IPP 2005 Inflatable Penile Prosthesis Cylinder, Pump, and Reservoir.
2. The subject has not had a previous penile prosthesis.
3. The subject is willing and able to give written valid Informed Consent.
4. The subject's reading level is judged adequate for reading and understanding the Informed Consent, patient questionnaires, and other study material
5. The subject is ≥ 21 years of age.
6. The subject has no known sensitivity to rifampin, minocycline or other tetracyclines as indicated in the device labeling.
7. The subject does not have systemic lupus erythematosus
8. The subject has the manual dexterity or mental ability to operate the pump.
9. The subject does not have active urogenital infection or active skin infection in region of surgery as indicated in the device labeling.
10. The subject is willing and able to return for follow-up evaluations and questionnaire completion according to the study protocol.
11. The subject is an acceptable risk for anesthesia and surgery.

Exclusion Criteria

Subjects will not be eligible for entry into this study if they meet any of the following criteria:
1. The subject's reading level is judged inadequate for reading and understanding the Informed Consent, patient questionnaires, and other study materials.
2. The subject is not willing or able to give written valid Informed Consent
3. The subject meets any of the following contraindications for InhibiZone™ use:

i. known allergy to or sensitivity to rifampin, minocycline, or to tetracyclines.

ii. diagnosed with systemic lupus erythematosus. d) The subject has a current Urinary Tract Infection (UTI), urogenital infection, or active skin infection in the region of surgery.

e) The subject does not have the manual dexterity or mental ability to operate the pump.

f) The subject has a compromised immune system. g) The subject refuses to, or is unable to, comply with the requirements of the protocol or return for follow-up visits.

h) The subject has been diagnosed with severe fibrosis due to priapism.
Minimum Eligible Age

21 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Medical Systems

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

L. Dean Knoll, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Research Associates of Nasville

Gerard D Henry, MD

Role: PRINCIPAL_INVESTIGATOR

Regional Urology LLC

Daniel Culkin, MD

Role: PRINCIPAL_INVESTIGATOR

University of Oklahoma Health Science Center

Dana A Ohl, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Juan Otheguy, MD

Role: PRINCIPAL_INVESTIGATOR

Advanced Research Institute

Ridwan Shabsigh, MD

Role: PRINCIPAL_INVESTIGATOR

New York Center for Human Sexuality

Steven K Wilson, MD

Role: PRINCIPAL_INVESTIGATOR

Institute for Urologic Excellence

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute for Urologic Excellence

Indio, California, United States

Site Status

Advanced Research Institute

New Port Richey, Florida, United States

Site Status

Regional Urology, LLC

Shreveport, Louisiana, United States

Site Status

University of Michigan School of Medicine

Ann Arbor, Michigan, United States

Site Status

New York Center for Human Sexuality

Brooklyn, New York, United States

Site Status

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

Medical Research Associates of Nashville

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Knoll LD, Henry G, Culkin D, Ohl DA, Otheguy J, Shabsigh R, Wilson SK, Delk Ii J. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med. 2009 Jun;6(6):1773-1778. doi: 10.1111/j.1743-6109.2009.01251.x. Epub 2009 Mar 30.

Reference Type RESULT
PMID: 19473458 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMS052

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Penile Injection Anxiety
NCT00582231 ACTIVE_NOT_RECRUITING